Dermira, Inc. (DERM) Director Sells $16,092.00 in Stock
Dermira, Inc. (NASDAQ:DERM) Director David E. Cohen sold 600 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $26.82, for a total value of $16,092.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of Dermira, Inc. (DERM) traded up $2.20 during mid-day trading on Friday, hitting $29.08. The company’s stock had a trading volume of 447,985 shares, compared to its average volume of 435,675. The company has a debt-to-equity ratio of 0.75, a current ratio of 24.43 and a quick ratio of 24.43.
Dermira (NASDAQ:DERM) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.04). Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. The firm had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.00 million. sell-side analysts predict that Dermira, Inc. will post -4.15 earnings per share for the current fiscal year.
A number of equities analysts recently issued reports on DERM shares. Zacks Investment Research cut Dermira from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Needham & Company LLC restated a “buy” rating and set a $46.00 price objective on shares of Dermira in a report on Tuesday, July 18th. Mizuho restated a “buy” rating and set a $43.00 price objective (up previously from $40.00) on shares of Dermira in a report on Thursday, September 7th. Cantor Fitzgerald reiterated a “buy” rating and issued a $45.00 target price on shares of Dermira in a report on Tuesday, September 26th. Finally, BidaskClub upgraded Dermira from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 16th. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $44.40.
Hedge funds have recently modified their holdings of the business. BNP Paribas Arbitrage SA lifted its holdings in shares of Dermira by 2,220.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 3,975 shares during the period. SG Americas Securities LLC raised its position in shares of Dermira by 66.8% in the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 2,203 shares in the last quarter. KCG Holdings Inc. bought a new position in shares of Dermira in the 1st quarter worth $215,000. Legal & General Group Plc raised its position in shares of Dermira by 16.3% in the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock worth $236,000 after acquiring an additional 963 shares in the last quarter. Finally, Ardsley Advisory Partners bought a new position in shares of Dermira in the 2nd quarter worth $291,000. Institutional investors and hedge funds own 97.67% of the company’s stock.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.